Mitotic Exit of Ovarian ancer Cells by Pharmaceutical hibition of the Anaphase-romoting Complex Reduces hromosomal Instability
onika Raab,Mourad Sanhaji,Shengtao Zhou,anz Rödel,Ahmed El-Balat,Sven Becker,laus Strebhardt
2019-01-01
Abstract:Paclitaxel is a frontline drug for the treatment of epithelial ovarian cancer (EOC). However, following paclitaxel-platinum based chemotherapy, tumor recurrence occurs in most ovarian cancer patients. Chromosomal instability (CIN) is a hallmark of cancer and represents genetic variation fueling tumor adaptation to cytotoxic effects of anticancer drugs. In this study, our Kaplan-Meier analysis including 263 ovarian cancer patients (stages I/II) revealed that high Polo-like kinase (PLK) 1 expression correlates with bad prognosis. To evaluate the role of PLK1 as potential cancer target within a combinatorial trial, we induced strong mitotic arrest in ovarian cancer cell lines by synergistically co-targeting microtubules (paclitaxel) and PLK1 (BI6727) followed by pharmaceutical inhibition of the Anaphase-Promoting Complex (APC/C) using proTAME. In shortand long-term experiments, this triple treatment strongly activated apoptosis in cell lines andprimary ovarian cells derived fromcancer patients.Mechanistically, BI6727/paclitaxel/proTAMEstabilizeCyclin B1 and trigger mitotic arrest, which initiates mitochondrial apoptosis by inactivation of antiapoptotic BCL-2 family proteins, followed by activation of caspase-dependent effector pathways. This triple treatment prevented endoreduplication and reduced CIN, two mechanisms that are associated with aggressive tumors and the acquisition of drug resistance. This “two-punch strategy” (strong mitotic arrest followed by blocking mitotic exit) has important implications for developing paclitaxel-based combinatorial treatments in ovarian cancer. Neoplasia (2019) 21, 363–375 breviations: CIN, chromosomal instability; APC/C, Anaphase-Promoting Complex; C, epithelial ovarian cancer; PLK1, polo-like kinase 1 dress all correspondence to: Prof. Dr. K. Strebhardt, Department of Gynecology, oethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main. ceived 17 January 2019; Accepted 29 January 2019 2019 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an en access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nd/4.0/). 76-5586 tps://doi.org/10.1016/j.neo.2019.01.007 troduction pithelial ovarian cancer (EOC) is a leading cause of cancer death in omen worldwide [1,2]. Microtubule targeting inhibitors like clitaxel represent one of the most important and promising classes cancer drugs used in the treatment of ovarian, breast, and lung cancer ,4]. TheGynecological Cancer Inter Group recommended in 2005 as andard of care for first-line chemotherapy the intravenous adminisation of paclitaxel in combination with carboplatin every 3 weeks for cycles [5,6]. Approximately two-thirds of ovarian cancer patients will spond to a therapeutical strategy that starts with surgical debulking d is followed by a paclitaxel/carboplatin-including chemotherapy, but mor recurrence occurs in most patients at a median of 15 months om initial diagnosis [7–9] often followed by chemoresistance. In dition to its role as first-line agent in a combined therapy, paclitaxel is promising agent for relapsed platinum-refractory epithelial ovarian ncer. However, the response to microtubule targeting agents is highly riable, which might interfere with clinical efficiency [10–12]. portantly, while certain side effects like myelosuppression are anageable, more problematic are the peripheral neuropathies induced inhibiting microtubule dynamics in nondividing cells [13]. nu at ch ub (A lig C st su fr ub C a pr ce pe E of pr th A pr m ov [2 pr hi m N at ad P ob fr w hi a ca an pr ea B m or sl fa un by tu is st 26 el in pa M